Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcq

Showing results (171-180 of 267) with videos related to

Pageof 27
Sort By:
Oncotarget|April 16, 2016
Hepatocyte SLAMF3 reduced specifically the multidrugs resistance protein MRP-1 and increases HCC cells sensitization to anti-cancer drugsGrégory Fouquet, Véronique Debuysscher, Hakim Ouled-Haddou, et al.
The French Journal of Urology|November 24, 2024
French AFU Cancer Committee Guidelines - Update 2024-2026: Muscle-invasive bladder cancer (MIBC)Mathieu Roumiguié, Gautier Marcq, Yann Neuzillet, et al.
World Journal of Urology|January 13, 2026
Surgical outcomes after neoadjuvant avelumab with or without chemotherapy for Muscle-Invasive bladder cancer: a Post-Hoc analysis of the aura trial (Oncodistinct-004)Georges Mjaess, Thierry Quackels, Jean-Christophe Fantoni, et al.
Oncotarget|January 23, 2016
RB/PLK1-dependent induced pathway by SLAMF3 expression inhibits mitosis and control hepatocarcinoma cell proliferationHicham Bouhlal, Hakim Ouled-Haddou, Véronique Debuysscher, et al.
Nature Physics|January 23, 2023
Mechanical stress driven by rigidity sensing governs epithelial stabilitySurabhi Sonam, Lakshmi Balasubramaniam, Shao-Zhen Lin, et al.
The French Journal of Urology|October 19, 2025
French recommendations of the AFU Oncology Committee for Bladder Cancer: Update 2025Mathieu Roumiguié, Evanguelos Xylinas, Pierre Etienne Gabriel, et al.
Pharmaceutics|December 23, 2022
Optimization of the Solvent and In Vivo Administration Route of Auranofin in a Syngeneic Non-Small Cell Lung Cancer and Glioblastoma Mouse ModelLaurie Freire Boullosa, Jinthe Van Loenhout, Christophe Hermans, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 11, 2025
Adjuvant radiotherapy in patients with pathological high-risk bladder cancer: Acute toxicity results from a randomized multicentre phase II trial (Bladder-ART/GETUG-AFU30)Paul Sargos, Géraldine Pignot, Carine Bellera, et al.
Frontiers in Toxicology|May 2, 2024
The MexTAg collaborative cross: host genetics affects asbestos related disease latency, but has little influence once tumours developScott A Fisher, Kimberley Patrick, Tracy Hoang, et al.
Cancer Management and Research|January 11, 2020
Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small-Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)Alain Vergnenègre, Victor Basse, Gwenaelle Le Garff, et al.
Pageof 27

Showing results (171-180 of 267) with videos related to

Sort By:
Pageof 27
Oncotarget|April 16, 2016
Hepatocyte SLAMF3 reduced specifically the multidrugs resistance protein MRP-1 and increases HCC cells sensitization to anti-cancer drugsGrégory Fouquet, Véronique Debuysscher, Hakim Ouled-Haddou, et al.
The French Journal of Urology|November 24, 2024
French AFU Cancer Committee Guidelines - Update 2024-2026: Muscle-invasive bladder cancer (MIBC)Mathieu Roumiguié, Gautier Marcq, Yann Neuzillet, et al.
World Journal of Urology|January 13, 2026
Surgical outcomes after neoadjuvant avelumab with or without chemotherapy for Muscle-Invasive bladder cancer: a Post-Hoc analysis of the aura trial (Oncodistinct-004)Georges Mjaess, Thierry Quackels, Jean-Christophe Fantoni, et al.
Oncotarget|January 23, 2016
RB/PLK1-dependent induced pathway by SLAMF3 expression inhibits mitosis and control hepatocarcinoma cell proliferationHicham Bouhlal, Hakim Ouled-Haddou, Véronique Debuysscher, et al.
Nature Physics|January 23, 2023
Mechanical stress driven by rigidity sensing governs epithelial stabilitySurabhi Sonam, Lakshmi Balasubramaniam, Shao-Zhen Lin, et al.
The French Journal of Urology|October 19, 2025
French recommendations of the AFU Oncology Committee for Bladder Cancer: Update 2025Mathieu Roumiguié, Evanguelos Xylinas, Pierre Etienne Gabriel, et al.
Pharmaceutics|December 23, 2022
Optimization of the Solvent and In Vivo Administration Route of Auranofin in a Syngeneic Non-Small Cell Lung Cancer and Glioblastoma Mouse ModelLaurie Freire Boullosa, Jinthe Van Loenhout, Christophe Hermans, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 11, 2025
Adjuvant radiotherapy in patients with pathological high-risk bladder cancer: Acute toxicity results from a randomized multicentre phase II trial (Bladder-ART/GETUG-AFU30)Paul Sargos, Géraldine Pignot, Carine Bellera, et al.
Frontiers in Toxicology|May 2, 2024
The MexTAg collaborative cross: host genetics affects asbestos related disease latency, but has little influence once tumours developScott A Fisher, Kimberley Patrick, Tracy Hoang, et al.
Cancer Management and Research|January 11, 2020
Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small-Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)Alain Vergnenègre, Victor Basse, Gwenaelle Le Garff, et al.
Pageof 27